Clinical trials: Streptococcus Pneumoniae
Streptococcus Pneumoniae Pneumonia
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07035054
- Testing
- low dose-1, low dose-2, high dose
- Where
- China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumococcal Immunization
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06736041
- Testing
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine
- Where
- 112 sites in United States, Australia and 4 more
- Volunteers
- 1,714 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Streptococcus Pneumoniae Pneumonia
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07025876
- Testing
- low dose PCV24, high dose PCV24, PPV23
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Acute Otitis Media (AOM)
Safety and Efficacy of wSp Vaccine in Young Children
The goal of this clinical trial is to evaluate whether the wSp vaccine can prevent nasopharyngeal colonization by pneumococcal bacteria in healthy young children who have received routine PCV15 or PCV20 vaccination.
- Trial name
- wSp005 (NCT07216430)
- Testing
- wSp vaccine, Saline (0.9% NaCl)
- Where
- 7 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Infections, Streptococcal
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
This is a booster study in 2 groups of healthy children less than 3 years old to measure the reactogenicity, safety and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine, when given as a booster or as a two-dose…
- Trial name
- NCT00513409
- Testing
- Synflorix, Infanrix Hexa, Havrix
- Where
- Chile
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
This study is designed to assess the safety, tolerability, and immunogenicity of V114 compared with Prevnar 13™ in healthy adults 65 years of age or older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
- Trial name
- NCT02573181
- Testing
- V114, Prevnar 13™
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis
The long-term goals of this study are (a) to understand the biological underpinnings for the increased incidence of community-acquired pneumonia in patients with chronic obstructive pulmonary disease (COPD) who are treated with…
- Trial name
- NCT03034642
- Testing
- Bronchoscopy with bilateral bronchoalveolar lavages
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Ann Arbor Healthcare System
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to…
- Trial name
- NCT00500357
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 16 sites in South Africa
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Children Aged 2-17 Years
A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years.
- Trial name
- NCT06550830
- Testing
- Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13®
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Disease
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years…
- Trial name
- NCT07023081
- Testing
- 20vPnC, 13vPnC
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine
This study is a single center , randomized ,controlled and open-label phase Ⅳclinical trial of the booster immunization with the third dose of inactivated COVID-19 vaccine(CoronaVac)manufactured by Sinovac Research \& Development…
- Trial name
- NCT05499351
- Testing
- Adult group in immunogenicity and safety study of combined immunization, Elderly group in immunogenicity and safety study of combined immunization, Adult group in safety observation study of combined immunization
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Invasive Pneumococcal Disease, Recurrent Isolated, 1, Invasive Pneumococcal Disease, Recurrent Isolated, 2
What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
This is a multicentre prospective audit to determine the incidence of immunodeficiency in children with IPD. Aims and/or research question of the project 1.
- Conditions
- Invasive Pneumococcal Disease, Recurrent Isolated, 1, Invasive Pneumococcal Disease, Recurrent Isolated, 2, Invasive Pneumococcal Disease, Protection Against, Primary Immunodeficiency
- Trial name
- NCT03815357
- Testing
- Referral to Immunology
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Pneumococcal Infections
Extension Safety and Immunogenicity Study of GPNV-001
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
- Trial name
- NCT05982314
- Testing
- Gamma-PN3, Pneumovax-23, Prevenar-13
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Pneumococcal Immunization, Healthy Volunteers
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06975878
- Testing
- PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine
- Where
- 49 sites in Belgium, Czechia and 6 more
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pneumococcal Vaccines
Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
A first-in-human, Phase 1 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)
- Trial name
- IVT PCV-25 (NCT05540028)
- Testing
- IVT PCV-25, PCV 20
- Where
- Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
HIV, Pneumococcal Infections
Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Human Immunodeficiency Virus (HIV) infection is complicated by high rates of infections and cancers which are often the cause of death rather than the HIV/acquired immune deficiency syndrome (AIDS) virus itself.
- Conditions
- HIV, Pneumococcal Infections, Pneumococcal Vaccines
- Trial name
- NCT02012309
- Testing
- PCV-13, PPSV-23
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Healthy
Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay
The study will identify healthy adults who have been vaccinated against pneumococcus, and collect blood for the purpose of developing laboratory assays.
- Trial name
- NCT00508950
- Testing
- Large volume blood draw
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers. This study is enrolling participants who are: Born after at least 36 weeks of pregnancy and about 2 months of…
- Trial name
- NCT05512819
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 11 sites in India, Taiwan
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Pfizer
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule
Assess immuno, reacto of the 10-valent pneumococcal vaccine after 2 doses (2, 4 months of age) and after the complete 2, 4, 11 months schedule when co-administered with DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (according to national…
- Trial name
- NCT00307034
- Testing
- GSK Biologicals' 10-valent pneumococcal conjugate vaccine., Infanrix hexa., Infanrix-IPV/Hib.
- Where
- 8 sites in Denmark, Norway and 2 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline